Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.
Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move...
The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $...
Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease (PD).
Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.
Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.
Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.
The addition significantly expands PCI's presence in the UK/EU to support global investigational studies of medicinal products by adding packaging, storage and distribution capacity, as well as consultative services for clinical trial supplies.
The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.
Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.
Mylan has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated.
Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).
VNE Corporation, a member of the worldwide Ehrenberg Group has announced the acquisition of HPT (High Purity Technologies), effective August 26, 2014. HPT Inc. was founded in 1983 and currently supplies industries with electropolished and O2 cleaned tubes and fittings for ultra high purity distributions systems and related applications.
MAVERICK, a supplier of industrial automation, enterprise integration and strategic manufacturing solutions, announced the acquisition of CQS Innovation, Inc., a Michigan-based systems integrator specializing in control and information systems for life sciences, chemical and metals industries.
PPD has acquired RCT Logic’s exclusive license from Massachusetts General Hospital for the portfolio of patents related to its sequential parallel comparison design (SPCD). SPCD is an alternative method for conducting well-controlled clinical trials that substantially decreases the impact on trial outcomes of any placebo effect.
Eisai today announced it has entered into an agreement with Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran.
DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.
VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.
Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...
Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Valeant Pharmaceuticals International announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.
Tekni-Plex, Inc. announced today that it has signed an agreement to acquire the assets of Tech-Seal Products, Inc. Tech-Seal manufactures closure liners and innerseals for food, pharmaceutical, cosmetic, and industrial applications.
New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.
Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.
- Page 1